Zobrazeno 1 - 10
of 116
pro vyhledávání: ''
Autor:
Zhenghua Lv, Xiuxiu Liu, Shengli Zhou, Xianfang Liu, Peihang Jing, Wei Xu, Shifeng Kan, Zhancheng Zhang
Publikováno v:
International Journal of Oncology
Cisplatin is a widely used platinum-based chemotherapeutic agent for hypopharyngeal squamous cell carcinoma (HSCC). However, resistance to cisplatin limits its use for the treatment of HSCC, and the underlying molecular mechanism requires further inv
Autor:
Zhangang Xiao, Jianhua Yin, Fukuan Du, Yuchen Zhang, Chengliang Huang, Yuanlin Wu, Parham Jabbarzadeh Kaboli, Jing Shen, Dandan Yuan, Chi Hin Cho, Xu Wu, Zhuo Zhang, Jing Li, Hanyu Zhang, Yueshui Zhao, Lan Lu, Mingxing Li
Publikováno v:
International Journal of Molecular Medicine
Cluster of differentiation 44 (CD44) as a transmembrane glycoprotein is found to be expressed in non-small cell lung cancer (NSCLC), is significantly associated with NSLC progression, metastasis and drug resistance. This study aimed to explore whethe
Publikováno v:
Molecular Medicine Reports
Aberrant expression of the epidermal growth factor receptor (EGFR) plays vital roles in tumor development and progression. In the present study, ultraviolet irradiation induced the upregulation of EGFR in skin-derived keratinocytes, which may contrib
Publikováno v:
Molecular Medicine Reports
Lung cancer is one of the leading causes of tumor-associated mortality, and >75% of patients with lung cancer have non-small cell lung cancer (NSCLC). Pemetrexed, a folate antagonist, is a first-line chemotherapy drug for NSCLC that is administered a
Autor:
Jianji Xu, Xiaoxiao Yu, Xiaoni Liu, Boxin Kou, Dexi Chen, Mengyin Chai, Yunjin Zang, Shuang Wang
Publikováno v:
International Journal of Oncology. 51:1291-1299
The present study was designed to investigate the synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 (Aspp2-ad) and oxaliplatin via p53-independent pathway in vitro and in vivo. After being treated with
Publikováno v:
International Journal of Oncology. 50:477-486
Bortezomib, formerly known as PS341, is a novel proteasome inhibitor with in vitro and in vivo antineoplastic effects in many malignancies. However, diverse antitumor mechanisms of bortezomib have been identified in many investigations and preclinica
Autor:
Shuta Tomida, Yu Nakamura, Hidetoshi Hayashi, Kazuko Sakai, Masato Terashima, Tetsuya Mitsudomi, Hiroshi Mizuuchi, Masato Chiba, Kazuto Nishio, Yosuke Togashi, Yoshihiko Fujita, Marco A. De Velasco, Eri Banno
Publikováno v:
International Journal of Oncology
Several receptor tyrosine kinases (RTKs) including EGFR, ALK, and MET have been identified as therapeutic targets in non-small cell lung cancer (NSCLC). Among the downstream pathways of RTKs, the MAPK pathway is particularly important for cancer cell
Autor:
Xing Xing Fan, Betty Yuen Kwan Law, Liang Liu, Paolo Coghi, Vincent Kam Wai Wong, Wu Zeng, Su-Wei Xu, Chung-Hang Leung, Elaine Lai-Han Leung, Dik-Lung Ma, Simon Wing Fai Mok
Publikováno v:
International Journal of Oncology. 49:1576-1588
Drug resistance of non-small cell lung cancer (NSCLC) is highly correlated to the mutation of the epidermal growth factor receptor (EGFR). Although EGFR tyrosine kinase inhibitors (TKIs) are available clinically, the molecular complexity of NSCLC has
Autor:
Denisa Margina, Valentina Anuta, Octavian Tudorel Olaru, Aristidis Tsatsakis, Demetrios A. Spandidos, George Mihai Nitulescu, Cristina Dinu Pirvu, Oana Cristina Seremet, Anca Zanfirescu, Georgiana Nitulescu
Publikováno v:
International Journal of Molecular Medicine
The use of alternative techniques to reduce the number of animals used in anticancer research is an issue of current interest. The aim of this study was to validate the use of a simple and efficient alternative tool for the assessment of the potentia
Autor:
Wei Zhou, Yixian Jing, Xiaolan Yang, Xiaolei Hu, Mingyue Zou, Fei Liao, Jinpeng Lu, Xin Wang, Bangtian Xu, Tingting Tong, Lei Xi
Publikováno v:
Oncology Reports.
The roles of glutathione S‑transferase pi 1 (GSTP1), glutathione S‑transferase mu 2 (GSTM2) and glutathione S‑transferase alpha 1 (GSTA1) in cisplatin (DDP)‑resistance of solid cancer cells (A549/DDP, SKOV3/DDP and SGC7901/DDP) were compared